Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2012 | 1 |
2017 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19.
N Engl J Med. 2017.
PMID: 28317415
Free article.
Clinical Trial.
The incidence of major bleeding events during and up to 8 weeks after ablation was lower with dabigatran than with warfarin (5 patients [1.6%] vs. 22 patients [6.9%]; absolute risk difference, -5.3 percentage points; 95% confidence interval, -8.4 to -2.2; P<0.001). Dabi …
The incidence of major bleeding events during and up to 8 weeks after ablation was lower with dabigatran than with warfarin (5 patients [1.6 …
Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder.
Etkin A, Maron-Katz A, Wu W, Fonzo GA, Huemer J, Vértes PE, Patenaude B, Richiardi J, Goodkind MS, Keller CJ, Ramos-Cejudo J, Zaiko YV, Peng KK, Shpigel E, Longwell P, Toll RT, Thompson A, Zack S, Gonzalez B, Edelstein R, Chen J, Akingbade I, Weiss E, Hart R, Mann S, Durkin K, Baete SH, Boada FE, Genfi A, Autea J, Newman J, Oathes DJ, Lindley SE, Abu-Amara D, Arnow BA, Crossley N, Hallmayer J, Fossati S, Rothbaum BO, Marmar CR, Bullmore ET, O'Hara R.
Etkin A, et al.
Sci Transl Med. 2019 Apr 3;11(486):eaal3236. doi: 10.1126/scitranslmed.aal3236.
Sci Transl Med. 2019.
PMID: 30944165
Free PMC article.
Clinical Trial.
Item in Clipboard
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.
Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium; Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group; Smith CG, West H, Cheadle JP; COIN Collaborative Group; Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.
Dunlop MG, et al.
Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.
Nat Genet. 2012.
PMID: 22634755
Free PMC article.
We identified three new CRC risk loci at 6p21 (rs1321311, near CDKN1A; P = 1.14 10(-10)), 11q13.4 (rs3824999, intronic to POLD3; P = 3.65 10(-10)) and Xp22.2 (rs5934683, near SHROOM2; P = 7.30 10(-10)) This brings the number of independent loci associated wit …
We identified three new CRC risk loci at 6p21 (rs1321311, near CDKN1A; P = 1.14 10(-10)), 11q13.4 (rs3824999, intronic to POLD3; P …
Item in Clipboard
Cholangiocyte myosin IIB is required for localized aggregation of sodium glucose cotransporter 1 to sites of Cryptosporidium parvum cellular invasion and facilitates parasite internalization.
O'Hara SP, Gajdos GB, Trussoni CE, Splinter PL, LaRusso NF.
O'Hara SP, et al.
Infect Immun. 2010 Jul;78(7):2927-36. doi: 10.1128/IAI.00077-10. Epub 2010 May 10.
Infect Immun. 2010.
PMID: 20457792
Free PMC article.
Concordantly, treatment of cells with the myosin light chain kinase inhibitor ML-7 or the myosin II-specific inhibitor blebbistatin or selective RNA-mediated repression of myosin IIB significantly inhibits (P < 0.05) C. parvum cellular invasion (by 60 to 80%). Furthermo
…
Concordantly, treatment of cells with the myosin light chain kinase inhibitor ML-7 or the myosin II-specific inhibitor blebbistatin or selec …
Item in Clipboard
Cite
Cite